Antiprogestin Drugs; Research and Clinical Use in Sweden
Law, Medicine and Health Care. 1992 Fall; 20(3): 157-160.
Dr. Marc Bygdeman and his co-author, Dr. Marja-Liisa Swahn, describe their pioneering contribution to the use of RU 486 as an abortifacient. Their work in Sweden, initially published in 1984, showed that the administration of RU 486 with subsequent use of a prostaglandin made RU 486 significantly more effective. They also explain their work determining the acceptability of the drug to women, and their finding that "it...seems unlikely that a medical abortion method with a limited duration of application will influence any significant number of indecisive women to perform an abortion which they would later regret." The authors describe their research on the use of combined RU 486/prostaglandin therapy for second trimester abortion, explaining that their initial findings show greater efficacy and decreased side effects and pain. Finally, they explain that their preliminary findings indicate that the use of RU 486 as a contraceptive administered after ovulation on a monthly basis may prove to be an attractive alternative to present contraceptive methods.
Showing items related by title, author, creator and subject.
Hilden, Hanna-Mari; Honkasalo, Marja-Liisa (2006-01)Our aim was to study how nurses interpret patient autonomy in end-of-life decision making. This study built on our previous quantitative study, which evaluated the experiences of and views on end-of-life decision making ...